#neogenchemicals notes with B&K securities :
🧪⚗️
Like and retweet !!
1. Products and contracts
During the lockdown the company received two long term contracts
i)Innovator pharma customer who is already purchasing some molecules from neogen
ii)International agro innovator with whom neogen is working for complex 6-7 stage molecules
After the VAM machines were introduced in India, Neogen was the first company to manufacture Lithium bromide required in VAM machines
Current revenue mix is 50% bromine 30% advance intermediates(10% CSM) and 20% lithium which will change to 40% bromine 40% advance intermediates (20% CSM) and 20% lithium.
2. Capex :
i) Good demand in pharma & agro but it was unmet due to insufficient capacity.
ii) Doubled lithium capacity
iii) Increasing Bromine -Organic capacity. Phase I completed. Phase II will get completed till Q3 start.
FY 22 revenues :450 Cr
FY 24 revenues :650 cr
3. Neogen Team :
i) Mr. surana from PI Indsutries is now on the board & he is an advisor. Dahej site got developed under his guidance.
ii) Employees increased from 200 to almost 400.
iiI) Haridas kanani (Founder 70 years +) focuses on r&d and selecting the right people
4. Customers :
i) It is not easy to please customers demand like thermax and voltas. (Lithium segment). As they demand premium quality. Neogen never turned down customer demands and tried to fulfil as much as possible
ii) Adopted CGMP practises from 2008
iii) Planning to add another segment for diversification (Probablt agrochem)
5. Chinese markets
i) Shortage of resources in China have caused innovators to outsource their products to India.
ii) International customers who worked with Chinese for 4-5 years shifted to neogen for new molecule due to lack of commitment & trasperency from manufactuer
iii) Stringent environment policy and high labor cost are slowing the momentum in china.
iv) China turned bromine importer from bromine exporter.
Conclusion :
Till now management is walking the talk. We should track the developments of 2nd phase of the bromine capex & how management handles the balance sheet!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Company overview: The Dharamsi Morarji Chemical Company Limited (DMCC) is a fully integrated speciality chemicals player in sulphur, boron and ethanol chemistry.
They have over 100 years of experience in sulphur chemistry and have also diversified their operations across other downstream products. Their products find usage in a wide range of industries such as pharmaceuticals, detergents, dyes, fertilisers, pigments and cosmetics.
Sequent Scientific just published their Annual Report for FY2021. Here are some of the key highlights. 1. 65% of revenue came from regulated markets whereas 35% came from less regulated markets.
Of this, 66% revenue was from formulations and 34% was from API. 2. Figures: ₹905Cr from Formulations and ₹456Cr from API
The business generated over ₹150Cr in cash from operations alone.
CFO/EBITDA for the year stood at 73.27%
3. Revenues for the formulation business were as follows : 46% Europe(3.8% yoy growth), 18% Turkey(37.3% yoy growth), 17% LATAM(78.5% yoy growth), 10% Emerging Markets(31.3% yoy decline), 9% India(98.4% yoy growth)
#valiantorganics Update : 1. OA capacity expanded to 4800 MT 2. ONA (Raw material for OA) capacity increased to 7200 MT. It will increase the margins. (New Product) 3. #PAP#paraaminphenol Production started. 200 MT in Q1 and expected to be 2300 MT in FY22. Total capacity 9000MT
4. Increased the stake in bharat chemicals from dhanvallabh venture LLP ( from 40 to 50%) 5. #bharatchemicals capacity of #paracetamol increased to 9000 MT 6. Raw material price increased in Q1, which will be passed on in Q2. #OA,#ONA,#PA,#PNA,#PAP will started contributing
7. New capex for #apis (chemicals for APIs). Mostly for apis manufactured by #aartiindustries and #aartidrugs
Intermediates will be manufactured for following APIs : 1. Ranolazine 2. Benazeprill 3. Elagolix 4. Pranlucast 5. Moxifloxacin 6. Ramipril 7. Montelukast 8. Quinapril
An analysis of #Sequent - India’s largest Animal Health Company
Like and retweet for more learnings 🐶🐕
A thread!🧵 1. Points covered : 2. Promoters and management 3. Company overview 4. Why is it different from human pharma 5. Opportunity size 6. Stability of business
7. FMCG like business 8. Barriers to entry 9. Manufacturing facilities 10. Summary of financials 11. Major acquisitions 12. Capex Details 13. Reduced Debt 14. Future Growth prospects 15. Valuation
Promoters and management
Carlyle Group - Private equity firm Carlyle Group acquired a majority stake in Sequent in 2020 and are the new promoters of the company. They have a lot of experience investing in the healthcare sector both in India and globally.
Here are some downstream derivatives for #phenol #Deepaknitrite will be doing 700 Cr capex for the products which are used in paints & coatings , lifesciences.
Check the following list & comment what can be downstream derivatives of #phenol ?
Like and retweet for more learnings🧪